In 2022, the ACT-Accelerator will intensify its drive for equity and scale in the delivery of essential COVID-19 tools, while carefully considering the evolution of the COVID-19 disease and development of medical countermeasures. The ACT-Accelerator has defined five strategic priorities for 2022:
Strategic priorities 2, 3 and 4 are ‘product’ priorities, focused on closing the substantial gaps towards the global targets for vaccines, tests, treatments and PPE, taking into account countries’ needs, capacities and preferences.
For vaccines, ACT-A will support countries in achieving their coverage ambitions, accelerating progress towards the 70% global vaccination target. For tests, ACT-A will help lagging countries advance testing rates to a minimum of 100 tests per 100,000 inhabitants per day.
Strategic priority 4 is focused on saving 120 million lives and protecting 2.7 million health workers in the face of sustained SARS-CoV-2 transmission, in LICs, LMICs and key UMICs. Under this strategic priority, ACT-A will focus on helping underserved countries close gaps in equitable access to new and existing COVID-19 treatments, including medical oxygen and personal protective equipment (PPE).
Strategic priority 5, is a ‘delivery’ priority and seeks to ensure that ACT-A’s Pillar delivery support is fully integrated with national COVID-19 response mechanisms. Through the revamped Health Systems & Response Connector, ACT-A will ensure that delivery support feeds into and enables wider response efforts, and that it interfaces more seamlessly with countries and their health systems.
In order to deliver on its overarching objective and new strategic priorities, ACT-A will adjust its ways of working in three ways: